Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer.
Adrenal Cortex Hormones
/ administration & dosage
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ administration & dosage
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ administration & dosage
Kaplan-Meier Estimate
Lung Neoplasms
/ drug therapy
Male
Metformin
/ administration & dosage
Middle Aged
Nivolumab
/ administration & dosage
Outcome Assessment, Health Care
/ methods
Probiotics
/ administration & dosage
Proportional Hazards Models
Proton Pump Inhibitors
/ administration & dosage
Retrospective Studies
NSAID
Nivolumab
antibiotics
corticoids
metformin
non-small cell lung cancer
proton pump inhibitors
statins
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
06
02
2020
revised:
24
02
2020
accepted:
29
02
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
21
4
2020
Statut:
ppublish
Résumé
To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.
Identifiants
pubmed: 32234916
pii: 40/4/2209
doi: 10.21873/anticanres.14182
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Bacterial Agents
0
Anti-Inflammatory Agents, Non-Steroidal
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Proton Pump Inhibitors
0
Nivolumab
31YO63LBSN
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2209-2217Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.